Dosing with an azolopyrimidine compound

Abstract

Provided herein are methods of treating a disease, disorder, or condition, mediated at least in part by the adenosine A 2A receptor (A 2A R) and/or the adenosine A 2B receptor (A 2B R) using Compound (I). In some embodiments, the disease or disorder is a cancer related disorder. Also provided herein are pharmaceutical compositions and single unit dosages of Compound (I).

1 - 67 . (canceled) 
     
     
         68 . A method of treating cancer comprising administering to a subject in need thereof a total daily dosage of about 5 to 250 mg of Compound I, having the formula: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, and a PD-1 antagonist or a PD-L1 antagonist. 
       
     
     
         69 . The method of  claim 68 , wherein the PD-1 antagonist is an antagonistic PD-1 antibody. 
     
     
         70 . The method of  claim 68 , wherein the PD-L1 antagonist is an antagonistic PD-L1 antibody. 
     
     
         71 . The method of  claim 68 , wherein said total daily dosage of Compound I is from about 50 to 150 mg per day. 
     
     
         72 . The method of  claim 68 , wherein said total daily dosage is about 75 mg per day. 
     
     
         73 . The method of  claim 68 , wherein said total daily dosage is from about 75 to 150 mg per day. 
     
     
         74 . The method of  claim 68 , wherein said total daily dosage is about 100 mg per day. 
     
     
         75 . The method of  claim 68 , wherein said total daily dosage is about 150 mg per day. 
     
     
         76 . The method of  claim 68 , wherein said Compound I is administered orally. 
     
     
         77 . The method of  claim 68 , wherein said Compound I is administered once daily. 
     
     
         78 . The method of  claim 68 , wherein said Compound I is administered twice daily. 
     
     
         79 . The method of  claim 68 , wherein said cancer is a cancer of the prostate, lung, bladder, kidney, pancreas, head and neck, lung, colon, rectum, or is sarcoma. 
     
     
         80 . The method of  claim 68 , wherein said cancer is prostate cancer. 
     
     
         81 . The method of  claim 68 , wherein said cancer is non-small-cell lung carcinoma. 
     
     
         82 . The method of  claim 68 , wherein said cancer is colorectal cancer. 
     
     
         83 . The method of  claim 68 , wherein said cancer is head and neck squamous cell carcinoma. 
     
     
         84 . The method of  claim 68 , wherein said cancer is renal cell carcinoma. 
     
     
         85 . The method of  claim 68 , wherein the cancer is metastatic. 
     
     
         86 . The method of  claim 68 , wherein the subject has received at least one prior line of therapy. 
     
     
         87 . The method of  claim 68 , further comprising administering a chemotherapeutic agent to the subject. 
     
     
         88 . The method of  claim 86 , wherein the chemotherapeutic agent is a taxoid, an antiandrogen, a platinum complex, a folate antagonist, a pyrimidine antagonist, or a combination thereof. 
     
     
         89 . The method of  claim 86 , wherein the chemotherapeutic agent is docetaxel, cisplatin, carboplatin, oxaliplatin, fluorouracil, or a combination thereof.